Circulating plasma cells as the most important prognostic biomarker in newly diagnosed multiple myeloma: Czech validation cohort
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F21%3A00075519" target="_blank" >RIV/65269705:_____/21:00075519 - isvavai.cz</a>
Result on the web
<a href="https://www.prolekare.cz/casopisy/transfuze-hematologie-dnes/archiv-cisel/2021-supplementum-2" target="_blank" >https://www.prolekare.cz/casopisy/transfuze-hematologie-dnes/archiv-cisel/2021-supplementum-2</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Circulating plasma cells as the most important prognostic biomarker in newly diagnosed multiple myeloma: Czech validation cohort
Original language description
Background: Tumor burden in multiple myeloma (MM) has always been evaluated in the bone marrow; nevertheless, it has never been implemented as a part of any risk stratification system due the lack of prognostic value. On the other hand, the quantification of circulating plasma cells (cPCs) from peripheral blood (PB) may be used as a surrogate of tumor burden as well as a powerful diagnostic bio marker. Aim: To validate the prognostic value of cPCs in newly diagnosed MM patients (as proposed by Garces, EHA 2021). Methods: CPCs were analyzed in PB by flow cytometry (FC) in 590 MM patients diagnosed between 2012 and 2019 at University Hospitals Brno and Ostrava. Patients were treated in real-world setting and the clinical analysis was performed retrospectively based on data from the Czech Registry of Monoclonal Gammopathies. Results: CPCs were detected in 74.6% (440/590) of newly diagnosed MM patients with applied threshold 20 cPCs and median of limit of detection 0.006% (range 0.0004-0.0391), sensitivity 10e5. Patients were stratified into 4 groups based on the FC percentage of cPCs [0% (N = 150), > 0% to < 0.24% (N = 307), GREATER-THAN OR EQUAL TO 0.24% to < 2.88% (N = 104) and GREATER-THAN OR EQUAL TO 2.88% (N=23)] that resulted in different progressionfree survival (PFS) (21.2 vs. 18.0, 15.1 and 5.1 months; P < 0.001) and in different overall survival (OS) (50.3 vs. 48.4, 31.7 and 17.6 months; P < 0.001). Quantification of cPCs was selected as the most powerful prognostic factor for survival by multivariable analysis including ISS, LDH and cytogenetics by Cox proportional hazard model. Conclusion: Evaluation of cPCs by FC in PB is the most important diagnostic biomarker that may be used for risk stratification of newly diagnosed MM as we demonstrated, up to our knowledge, on the largest dataset worldwide.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
<a href="/en/project/NV18-03-00203" target="_blank" >NV18-03-00203: Liquid biopsies in plasma cell leukemia</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů